152 related articles for article (PubMed ID: 38654028)
1. Simultaneous boost radiotherapy versus conventional dose radiotherapy for patients with newly diagnosed glioblastoma: a multi-institutional analysis.
Takano S; Tomita N; Kuno M; Niwa M; Torii A; Takaoka T; Kita N; Okazaki D; Yamamoto S; Kawai T; Sugie C; Ogawa Y; Matsumoto K; Uchiyama K; Otsuka S; Matsui T; Miyakawa A; Mizuno T; Iida M; Tanikawa M; Mase M; Hiwatashi A
Sci Rep; 2024 Apr; 14(1):9283. PubMed ID: 38654028
[TBL] [Abstract][Full Text] [Related]
2. Effect of intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy on clinical outcomes in patients with glioblastoma multiforme.
Chen YD; Feng J; Fang T; Yang M; Qiu XG; Jiang T
Chin Med J (Engl); 2013 Jun; 126(12):2320-4. PubMed ID: 23786946
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy.
Matsuda M; Yamamoto T; Ishikawa E; Nakai K; Zaboronok A; Takano S; Matsumura A
Br J Radiol; 2011 Dec; 84 Spec No 1(Spec Iss 1):S54-60. PubMed ID: 21427185
[TBL] [Abstract][Full Text] [Related]
5. Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection.
Chen L; Guerrero-Cazares H; Ye X; Ford E; McNutt T; Kleinberg L; Lim M; Chaichana K; Quinones-Hinojosa A; Redmond K
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):616-22. PubMed ID: 23540348
[TBL] [Abstract][Full Text] [Related]
6. Initial Results of a Phase 2 Trial of
Laack NN; Pafundi D; Anderson SK; Kaufmann T; Lowe V; Hunt C; Vogen D; Yan E; Sarkaria J; Brown P; Kizilbash S; Uhm J; Ruff M; Zakhary M; Zhang Y; Seaberg M; Wan Chan Tseung HS; Kabat B; Kemp B; Brinkmann D
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1383-1395. PubMed ID: 33771703
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial.
Ballo MT; Urman N; Lavy-Shahaf G; Grewal J; Bomzon Z; Toms S
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1106-1113. PubMed ID: 31026557
[TBL] [Abstract][Full Text] [Related]
9. Survival of glioblastoma treated with a moderately escalated radiation dose-Results of a retrospective analysis.
Shieh LT; Guo HR; Ho CH; Lin LC; Chang CH; Ho SY
PLoS One; 2020; 15(5):e0233188. PubMed ID: 32413077
[TBL] [Abstract][Full Text] [Related]
10. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme.
Monjazeb AM; Ayala D; Jensen C; Case LD; Bourland JD; Ellis TL; McMullen KP; Chan MD; Tatter SB; Lesser GJ; Shaw EG
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):743-8. PubMed ID: 21236604
[TBL] [Abstract][Full Text] [Related]
11. Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma.
Zschaeck S; Wust P; Graf R; Misch M; Onken J; Ghadjar P; Badakhshi H; Florange J; Budach V; Kaul D
Radiat Oncol; 2018 Dec; 13(1):251. PubMed ID: 30567592
[TBL] [Abstract][Full Text] [Related]
12. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
13. Fractionated Stereotactic Sequential Boost in a Selected Cohort of Glioblastoma Patients: A Mono-institutional Analysis.
Marchionni A; Palumbo I; Montesi G; Bini V; Zucchetti C; Cenci N; Chiarini P; Saccia S; Aristei C; Lupattelli M
Anticancer Res; 2020 Jun; 40(6):3387-3393. PubMed ID: 32487635
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
[TBL] [Abstract][Full Text] [Related]
15. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
[TBL] [Abstract][Full Text] [Related]
16. Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme.
Fuller CD; Choi M; Forthuber B; Wang SJ; Rajagiriyil N; Salter BJ; Fuss M
Radiat Oncol; 2007 Jul; 2():26. PubMed ID: 17629934
[TBL] [Abstract][Full Text] [Related]
17. Intensity modulated radiation therapy (IMRT) for sinonasal tumors: a single center long-term clinical analysis.
Askoxylakis V; Hegenbarth P; Timke C; Saleh-Ebrahimi L; Debus J; Röder F; Huber PE
Radiat Oncol; 2016 Feb; 11():17. PubMed ID: 26847089
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
19. Clinical and dosimetric study of radiotherapy for glioblastoma: three-dimensional conformal radiotherapy versus intensity-modulated radiotherapy.
Thibouw D; Truc G; Bertaut A; Chevalier C; Aubignac L; Mirjolet C
J Neurooncol; 2018 Apr; 137(2):429-438. PubMed ID: 29374810
[TBL] [Abstract][Full Text] [Related]
20. Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients.
Munck Af Rosenschold P; Law I; Engelholm S; Engelholm SA; Muhic A; Lundemann MJ; Roed H; Grunnet K; Skovgaard Poulsen H
Radiother Oncol; 2019 Jan; 130():149-155. PubMed ID: 30446316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
